AMRN Overview
Upcoming Projects (AMRN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AMRN)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (AMRN)
-
Discussing the future of Amarin, with recent Vascepa litigation & new data in the spotlight
Ticker: AMRN
Execute By: Jun 12, 2020
Upcoming & Overdue Catalysts (AMRN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (AMRN)
-
REDUCE-IT Study of Vascepa (icosapent ethyl) Remains On-Track for Report of Top-Line Results Before the End of September 2018
Ticker: AMRN
Occurred on: Sep 24, 2018 -
Interim Analysis of REDUCE-IT Cardiovascular Outcomes Trial of Vescepa Expected Late 2016
Ticker: AMRN
Occurred on: Sep 12, 2016 -
Amarin and FDA Reaffirm Concurrence on REDUCE-IT Through Special Protocol Assessment Agreement Amendment
Ticker: AMRN
Occurred on: Aug 04, 2016 -
Vascepa (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels
Ticker: AMRN
Occurred on: May 20, 2016 -
Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation - Allows Off-label Promotion of Vescepa
Ticker: AMRN
Occurred on: Mar 09, 2016 -
Amarin and FDA both file to push back court date of Amarin First Amendment litigation to March 18, 2016 as settlement talks ensue
Ticker: AMRN
Occurred on: Mar 09, 2016
Strategic Initiatives (AMRN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
